A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8+ T Cells Authors: Amir Saeid Mahdavi, Nader Bagheri, Francesco M Marincola, Pegah Khosravian, Mahdi Ghatrehsamani Published: 2026 ABSTRACT AbstractBackgroundBreast cancer (BC) is the most prevalent cancer among women, and retrieving the anti-tumor function of the immune system seems a promising treatment approach for its crucial role in combating cancer cells. In this study, we evaluated the impact of a combination therapy containing a TAK1 inhibitor, Takinib (Tak), a metabolic regulator, Metformin (Met), and an immunostimulant, Lentinula edodes mycelia extract (LEME) on enhancing the immune system’s anti-tumor activity in BALB/c mice bearing triple-negative breast cancer (TNBC).MethodsBALB/c mice were used to induce TNBC tumors and evaluate tumor growth inhibition. The number of CD8+ CD28+ T cells was determined by immunofluorescence assay, the expression of MUC1 protein was assessed by Western blot, while the expression of TOX, NR4A1, and TIM-3 genes was evaluated by real-time PCR in mouse-derived tumor tissues. MTT assay was performed on different BC cell lines to assess cell viability.ResultsMolecular docking results revealed significant interactions between Tak and Met with TOX and NR4A1. The combination treatments of Tak, Met, and LEME significantly decreased tumor volume/weight in mice and also significantly increased the number of infiltrated CD8+ CD28+ T cells, reduced MUC-1 protein expression, and decreased the expression of TOX, NR4A1, and TIM-3 genes in mouse tumor tissue. Tak, Met, and their combination significantly decreased the cell viability of different BC cell lines.ConclusionThis study suggests that the Tak–Met–LEME combination treatments may inhibit BC progression by increasing CD8+ CD28+ T cell population in tumor tissue and decreasing tumor progression.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-026-07905-9.Keywords: Takinib, Metformin, Lentinula edodes, Combination therapy, Triple-negative breast cancer, CD8+ CD28+ T cells Introduction According to the latest World Health Organization (WHO) reports, breast cancer (BC) is the most common cancer among women and significantly impacts their quality of life. BC is the second leading cause of death in women and remains a significant health challenge worldwide [1]. BC is classified into five types based on the expression of receptors such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) on its surface [2, 3]. Triple-negative breast cancer (TNBC) lacks expression of all these receptors. TNBC holds significant clinical importance due to accounting for a substantial proportion of BC cases and associated features such as invasiveness and a high tendency to metastasize to other tissues [4, 5]. Chemotherapy remains a widely used and preferred treatment for breast cancer; however, despite the evaluation of numerous compounds in studies, the development of new therapeutic approaches is still essential due to variable efficacy, adverse side effects, and the emergence of drug resistance in tumor cells [6, 7]. Enhancing immune system function, which highlights the crucial role of the immune system in combating cancer cells, presents a promising approach. Additionally, combination therapy has emerged as a promising strategy to enhance treatment effectiveness and overcome drug resistance in cancer [8–10]. Developing effective combination therapies requires an accurate understanding of the tumor microenvironment (TME) and the function of immune cells within this environment [11–13]. CD8+ T cells are the most important immune cells responsible for eliminating tumor cells in the TME and play a critical role in controlling the disease [14–16]. Conversely, the TME not only promotes tumor growth and metastasis but also suppresses anti-tumor immunity by inducing dysfunctional CD8 + T cells through mechanisms such as chronic antigen stimulation, excessive production of reactive oxygen species (ROS), and the presence of immunosuppressive cytokines (IL-10, TGF-β) (10, 11) alongside pro-inflammatory cytokines (IL-6, TNF-α) [17, 18]. Senescence and exhaustion are the most important and recognized phenotypes of non-functional CD8+ T cells [19]. These phenotypes share common features such as a lack of expression of co-stimulatory receptors like CD28, which plays a crucial role in CD8+ T cells function to exert their anti-cancer activity [20, 21], or expression of inhibitory receptors like programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Exhausted CD8 + T cells are also unable to secrete homeostatic cytokines and display reduced proliferative capacity [22, 23]. Studies have revealed that specific transcription factors regulate the exhaustion and senescence of CD8+ T cells [24]. Among them, the nuclear receptor group 4 family A (NR4A1) and the thymocyte selection-associated HMG-box protein (TOX) are particularly important due to their crucial role in inducing T cell exhaustion. Chronic antigen stimulation in T cells leads to the continuous activation of the nuclear factor of activated T cells (NFAT), which in turn activates its targets, including NR4A1 and TOX. NR4A1 and TOX cooperate to upregulate inhibitory markers, such as PD-1 and TIM3, on CD8+ T cells, thereby promoting the development of dysfunctional CD8+ T cells [25]. Transforming growth factor-β-activated kinase 1 (TAK1) is a protein kinase that plays a key role in regulating cell death and survival. Also, regulating inflammation through activating factors like NF-κB and mitogen-activated protein kinases (MAPKs) [26, 27]. Takinib (Tak) is a selective TAK1 inhibitor with high binding affinity, and recent studies have demonstrated its anti-inflammatory and anti-cancer effect [28]. Tak inhibits tumor survival pathway downstream of TNFRI in cancer cells and suppresses tumor growth after stimulation with TNF-α in TME [29]. Also, Tak reduces the activation of senescence-associated factors such as NF-kB and p38, following engagement of TNF-α to TNFRII in immune cells [30]. In addition, exploiting metabolic regulators is a desirable approach for BC therapy [31]. Metformin (Met) is an antidiabetic drug that reduces tumor growth and improves immune system function. Also, Met reduces exhaustion phenotypes in T lymphocytes by regulating mitochondrial biogenesis and modulating oxidative stress [32]. In combination with these anti-inflammatory agents, compounds that enhance the anti-tumor function of immune cells represent a promising approach for cancer treatment. The filamentous mushroom Lentinula edodes, known as Shiitake, has been used for a long time in traditional Chinese medicine [33]. Lentinula edodes mycelia extract (LEME) contains diverse compounds that bind to innate immune receptors on immune cells and increase the secretion of specific cytokines like IL-12, IL-18, and IFN-γ, which upregulate the expression of co-stimulatory receptors such as NKG2D and NCR, on NK cells and CD8+ T cells [34]. Computational docking analysis was used to predict any potential interactions between therapeutic agents (Tak and Met) and target proteins (NR4A-1, TOX and TIM-3). In this study, we investigated the therapeutic potential of a combination therapy comprising the TAK1 inhibitor (Tak), the metabolic modulator (Met), and the immunostimulant compound extracted from Lentinula edodes (LEME) in BALB/c mice bearing a TNBC tumor. Methods and materials Reagents and antibodies Cell culture media and other required materials for cell culture were purchased from Gibco (Grand Island, NY, USA) and Sigma Aldrich (St. Louis, MO, USA). Metformin-HCl (Cat No: M0605000) was obtained from Sigma Aldrich. Takinib (EDHS-206) (Cat No: HY-103490) was purchased from MedChemExpress and dissolved in sterile DMSO. Shiitake mushroom extract obtained from Selleckchem (Cat No: E3757). MTT powder (Cat. No.: 298931) was obtained from Sigma-Aldrich. Rabbit polyclonal antibody against MUC-1 was purchased from Saint John’s Laboratory (Cat: STJ97312). The mouse polyclonal antibody against β-actin was obtained from Santa Cruz Biotechnology (Cat: sc-47778, RRID: AB_626632). Goat Anti-mouse and Anti-rabbit IgG H&L (HRP) were purchased from Abcam (Cat: ab97023; RRID: AB_10679675 and Cat: ab6721, RRID: AB_955447). Immunofluorescence assay performed using rabbit polyclonal antibodies against CD8 with goat anti-rabbit IgG as secondary antibody (Biorbyt, orb323288 and orb688925) and mouse monoclonal antibody against CD28 (GeneTEx, GTX13463) with goat anti-mouse IgG as secondary antibody (Santa Cruz Biotechnology, sc-3738). DAPI for nucleic acid staining was obtained from Sigma-Aldrich (D9542). Other materials and reagents, such as solvents, buffers, and salts, were purchased from Merck (Darmstadt, Germany). Bioinformatic study Molecular docking The target proteins’ three-dimensional (3D) structures were obtained from the Protein Data Bank (PDB) when available, or homology modeling was employed using Alpha-Fold for targets lacking experimentally resolved structures [35]. Molecular docking was carried out to investigate the potential interactions between Met (PubChem CID: 4091) and Tak (PubChem CID: 37750349) with selected immunoregulatory protein targets, including TOX (PDB: 2co9), NR4A1 (PDB: 7M3Z), and TIM-3 (PDB: 3V3E). The protein structures were prepared using AutoDock Tools (ADT) and Chiemrea.x 1.9 by removing water molecules, adding polar hydrogen atoms, and assigning Kollman charges. Ligand structures were retrieved from the PubChem database, energy minimized using the MMFF94 force field in Avogadro, and converted to PDBQT format using OpenBabel [36]. Docking simulations were performed using AutoDock Vina, with defined grid boxes covering each protein’s predicted active or functional domains. The grid box parameters were determined based on prior knowledge of ligand-binding sites. The exhaustiveness parameter was set to 8, with a maximum of 9 binding modes generated per docking run. Output conformations were ranked according to predicted binding affinity (kcal/mol), and the lowest binding energy pose was selected as the representative binding mode. Docked complexes were further analyzed using PyMOL for 3D visualization of binding orientation. PLIP and POSEview were used to generate two-dimensional interaction diagrams to identify hydrogen bonding and hydrophobic interactions [37]. Cellular experiments Cell culture The MCF-7 and MDA-MB 231 human BC cell line, and 4T1 mouse TNBC cell line was purchased from the Pasteur Institute and cultured in RPMI 1640 (Gibco, Invitrogen, UK) medium containing 10% fetal bovine serum, 1% penicillin (100 mL/u)/streptomycin (100 g/mL) and glutamine (3 mg/mL) then maintained in a humidity incubator at 37 °C with 5% CO₂ and 95% humidity. Cell viability assay The cytotoxic effects of Met, Tak, and their combination on different BC cell lines, including human BC cell lines, such as MCF-7 and MDA-MB-231, and the 4T1 mouse TNBC cell line, were investigated using the MTT assay. Cells were trypsinized and counted, then 5,000 cells in 100 µl media were added to each well of a 96-well microplate. After 24 h, cells were treated with Met at 181 mM [38] and Tak at 0.9 mM [39] in single and combined groups, and then incubated at 37 °C with 5% CO₂ and 95% humidity for 24 and 48 h. The concentrations used for cell viability evaluation correspond to those used in the mice in vivo experiment based on previous studies. MTT assay performed for assessing cell proliferation. Each well was treated with an MTT solution (5 mg/mL in phosphate-buffered saline, PBS) and incubated at 37 °C for 4 h. Then, cells were exposed to 100 µL of DMSO solution, and the mixture was allowed to stand in the dark for 15 min. Finally, an ELISA microplate reader (Labsystem Multiskan, Labsystem, Helsinki, Finland) was used to measure the absorbance at a wavelength of 595 nm, with a background absorbance measurement at 630 nm. Finally, the Bliss Independence Model was utilized as a mathematical approach for assessing drug interactions and synergism analysis. In vivo assessment In vivo triple-negative breast cancer tumor inoculation in BALB/c mice To investigate the treatment effects in vivo, 40 female BALB/c mice (4 weeks old, weighing 20–25 g) were obtained from the Pasteur Institute and maintained under sterile conditions with free access to food, water, and natural light. A total of 2 × 10⁶ 4T1 cells, suspended in sterile PBS, were subcutaneously injected into the right flank of each mouse [40]. When the tumor volume reached approximately 50 mm³ (10–13 days after induction), the mice were randomly divided into eight groups, including a control group [41]. The treatment groups received Met (150 mg/kg/day, intraperitoneally) [38], Tak (0.9 mM or 145 µg/kg, intravenously, 10 µl volume, three times per week) [39], and LEME (18 mg/mouse/day, oral gavage) [42], either as single agents or in combination. The control group received saline for a period of 4 weeks. Tumor volume (TV) was measured every 3 days using a caliper and calculated using the formula: V = ½ (Length × Width²), where L represents tumor length and W tumor width [43]. Mice’s body weights were recorded every 3 days. According to ethical guidelines, mice with tumor volumes exceeding 1000 mm³ were euthanized [44]. At the end of the 4-week treatment period, mice were euthanized by intraperitoneal administration of ketamine/xylazine (80–100 mg/kg ketamine and 10 mg/kg xylazine) [45]. Following euthanasia, tumors were excised and measured for volume and weight, then bisected. One-half was immediately stored at − 70 °C for real-time PCR and Western blot analyses, while the other half was fixed in 10% formaldehyde for histopathological examination. All in vivo experiments of the study, including euthanasia, were conducted in accordance with the guidelines laid out by the Shahrekord University of Medical Sciences’ Laboratory Animal Center in Shahrekord, Iran (Ethical Code: IR.SKUMS.AEC.1403.061), and followed the internationally accepted standards for animal research, including the ARRIVE guidelines, the NIH Guide and the guidelines provided by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Real-time PCR gene expression Initially, RNA was extracted from tumor tissue using an RNA extraction kit (Thermo Fisher Scientific). Then RNA concentration and purity were assessed using a NanoDrop spectrophotometer (260/280 absorbance ratio). Complementary DNA (cDNA) was synthesized using a cDNA synthesis kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Quantitative PCR (qPCR) was performed using SYBR Green master mix (SMO BIO) on a Rotor-Gene 3000 instrument [46]. The amplification protocol consisted of initial enzyme activation at 95 °C for 10 min, followed by 40 cycles of denaturation (95 °C, 15 s) and annealing/extension (60 °C, 60 s), with final melt curve analysis. We evaluated expression of exhaustion-related genes (TOX, NR4A1, and TIM-3). Primer sequences are shown in Table 1. Gene expression was normalized to the B2M housekeeping gene. For quantitative real-time PCR analysis, relative gene expression was calculated using the 2™ΔΔCt method and presented as a fold change relative to the control. Statistical analyses were performed on ΔCt values before fold-change transformation [47], based on the efficiency of the primers used in amplifying this study. Table 1Primer sequence used for real-time PCR analysisTargetSequenceTemperatureTOXforward 5ʹ - TCC CGT TCC ATC CAC AAA CC − 3ʹreverse 5ʹ - TGC CTG CTG TCT GAT GTC TG − 3ʹ60NR4A1forward 5ʹ -ACA GAA AGG AAG AGG TTG AGA TGG − 3ʹreverse 5ʹ- TGG AAG GAG AGC GGA AGA GA -3ʹ60TIM-3forward 5ʹ - CTA CAT CGG AGC AGG GAT − 3ʹreverse 5ʹ - CTG AGG GAG GGA GGT TG − 3ʹ60B2Mforward 5ʹ - TGG TTT CTG GTG CTT GTC T − 3ʹreverse 5ʹ-CAG TTC AGT ATG TTC GGC TTC C -3ʹ60 Primer sequence used for real-time PCR analysis forward 5ʹ - TCC CGT TCC ATC CAC AAA CC − 3ʹ reverse 5ʹ - TGC CTG CTG TCT GAT GTC TG − 3ʹ forward 5ʹ -ACA GAA AGG AAG AGG TTG AGA TGG − 3ʹ reverse 5ʹ- TGG AAG GAG AGC GGA AGA GA -3ʹ forward 5ʹ - CTA CAT CGG AGC AGG GAT − 3ʹ reverse 5ʹ - CTG AGG GAG GGA GGT TG − 3ʹ forward 5ʹ - TGG TTT CTG GTG CTT GTC T − 3ʹ reverse 5ʹ-CAG TTC AGT ATG TTC GGC TTC C -3ʹ Protein extraction and western blot Proteins were extracted from TNBC tumor tissue using cold RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1–5 mM EDTA, with protease/phosphatase inhibitors). Protein concentration was determined using the Bradford assay with BSA standard curves [48]. Protein samples were mixed with 4× loading buffer, heated at 95 °C, and separated on 12% SDS-polyacrylamide gels. Proteins were transferred to PVDF membranes (Pall Corporation) by semi-dry electroblotting. Membranes were blocked with skim milk for 4 h, then incubated overnight at 4 °C with shaking with primary antibodies, followed by incubation with HRP-conjugated secondary antibodies for 2 h at room temperature. β-actin served as a loading control [48]. Protein bands were visualized using ECL (Thermo Scientific) and imaged with a Canon camera. Band densitometry was performed using ImageJ software. Immunofluorescence assay Tumor tissues were embedded in paraffin, sectioned at 4 μm using a microtome, and transferred to poly-L-lysine-coated slides. The sections were then incubated at 90 °C for 30 min. Deparaffinization was performed by immersing slides in xylene (5–10 min, three times), followed by graded ethanol treatment. Antigen retrieval utilized heat-induced epitope retrieval (HIER) by heating slides in citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6.0) in a microwave for 30 min [49]. Slides were blocked with 5% BSA in PBS for 30 min at room temperature, then incubated overnight at 4 °C with primary antibodies against CD8 and CD28. Subsequently, slides were incubated with goat anti-rabbit and goat anti mouse IgG secondary antibody for 60 min at room temperature. Nuclear staining was performed using DAPI (1 mg/mL), and slides were mounted with fluorescence-preserving mounting medium. Fluorescent signals were visualized using an Olympus confocal laser scanning microscope. Five random fields (1 mm²) enriched in immune cells were selected for quantitative analysis. CD8+CD28+ T lymphocytes were quantified using ImageJ software (version 1.52 h) at both 40× and 10× magnification. Statistical analysis Statistical analysis was performed using GraphPad Prism 10.5.0 version (GraphPad Software, La Jolla, CA). The Kolmogorov-Smirnov test assessed normality. Following that, an analysis of variance (ANOVA) along with a suitable post hoc test (Dunnett and Tukey’s test) was performed to compare the groups both with the control group and among themselves. Finally, results are presented as mean ± standard error of the mean (SEM). A p-value of ≤ 0.05 was considered statistically significant. Results Bioinformatic study Molecular docking Molecular docking analysis was performed to evaluate the binding affinities of Met, Tak, and the standard ligand with NR4A1 (shown in Fig. 1). The docking scores (binding free energies, kcal/mol) are summarized in Table 2. Tak may have a higher potential binding affinity among the tested ligands, with the best docking score of − 7.8 kcal/mol, compared to − 5.2 kcal/mol for Met and − 3.8 kcal/mol for the standard ligand. Molecular docking analysis of Tak and Met binding to NR4A1. (A) Surface representation of the NR4A1 protein displaying the binding pocket with Met positioned within the active site. The magnified inset reveals the detailed binding orientation of Met in the receptor cavity. Two-dimensional interaction diagram depicting the hydrogen bonding network between Met and key amino acid residues. Met establishes hydrogen bonds with Leu42, Pro46, and Arg123 (indicated by dashed lines), resulting in a moderate binding affinity of -5.2 kcal/mol. Met demonstrates statistically significant binding to NR4A1 compared to the standard ligand (-3.8 kcal/mol). (B) Showing the NR4A1 binding site with Tak docked in the active site. Two-dimensional interaction diagram illustrating the hydrogen bonding network between Tak and critical amino acid residues. Key interactions include hydrogen bonds with Pro18A, Ala74A, and Gln19A (shown as dashed lines), which contribute to the compound’s high binding affinity (-7.8 kcal/mol) Table 2Docking affinities and hydrogen bond interactions between ligands and targetsLigandBest binding affinity (kcal/mol)Mean ± SD (9 modes)Residues interacting in hydrogen bondsBond length (Å)NR4A1Met–5.2–4.3 ± 0.5LEU42, PRO46, ARG1231.9–3.2Tak–7.8–7.1 ± 0.3LYS125, HIS163, VAL1672.0–2.3Standard–3.8–3.5 ± 0.3-- TOX Met–4.0–3.7 ± 0.2GLN192.67–3.15Tak–6.5–6.2 ± 0.2GLN19, ALA742.19–3.04 TIM-3 Met–3.7–3.3 ± 0.2--Tak–5.9–5.6 ± 0.2--Standard–7.7–7.0 ± 0.3-- Docking affinities and hydrogen bond interactions between ligands and targets Hydrogen bond analysis revealed distinct interaction patterns (Table 2). Met established hydrogen bonds with LEU42, PRO46, and ARG123, while Tak predicted to have stable hydrogen bonds with LYS125, HIS163, and VAL167. The standard ligand exhibited weaker interactions, lacking a consistent hydrogen bond network comparable to that of the other compounds. Computational modeling suggested that Tak exhibited stronger predicted binding affinity to NR4A1 than Met based on docking scores and hydrogen bonding interactions. However, it is essential to emphasize that these are theoretical predictions that require experimental validation. Blinded molecular docking was performed to evaluate potential interactions of Met and Tak with the TOX protein (shown in Fig. 2). Since no standard ligand was available, the analysis focused on comparative binding affinities and docking mode distributions. Molecular docking analysis of Tak and Met binding to TOX. (A) Surface representation of the TOX protein displaying the binding pocket with Met positioned within the receptor cavity. The magnified inset shows the detailed binding pose of Met. Two-dimensional interaction diagram depicting the hydrogen bonding between Met and TOX. Met establishes a single hydrogen bond with Gln19 (indicated by dashed line), resulting in a moderate binding affinity of -4.0 kcal/mol. The limited hydrogen bonding network reflects weaker binding interactions compared to Takinib, suggesting lower potential for TOX protein modulation. (B) Representing the TOX protein binding site with Tak docked within the receptor. The inset provides a magnified view of Tak’s binding conformation in the active site. Tak forms two hydrogen bonds with Gln19 and Ala74 (shown as dashed lines), contributing to its superior binding affinity of -6.5 kcal/mol. The dual hydrogen bonding network supports Tak’s consistent and favorable interaction with the TOX protein Docking scores from the top nine predicted binding modes are summarized in Table 2. Tak was predicted to bind TOX by higher affinity, exhibiting a best docking affinity of − 6.5 kcal/mol, compared to − 4.0 kcal/mol for Met. The average binding energies across all modes were − 6.2 ± 0.2 kcal/mol for Tak and − 3.7 ± 0.2 kcal/mol for Met, suggesting a consistent trend of higher binding strength for Tak. These results indicate that Tak may have a higher potential to interact with TOX than Met. Additionally, the hydrogen bond between TOX and Tak and Met was investigated (Table 2). Met established only one hydrogen bond with GLN19, while Tak formed two hydrogen bonds with GLN19 and ALA74. Docking analysis of Met, Tak, and the standard ligand against TIM-3 revealed distinct binding affinities (Table 2). Tak was predicted to have intermediate binding strength, with the best docking score of − 5.9 kcal/mol, whereas Met exhibited weaker binding (–3.7 kcal/mol). The standard ligand displayed the strongest predicted binding, with a top score of − 7.7 kcal/mol. The RMSD values for multiple docking modes indicated that each ligand explored several conformations, suggesting flexibility in binding orientation. The top-ranked poses were generally well-clustered, supporting the stability of the predicted interactions. These results predicted that the standard ligand has the highest potential to interact with TIM-3, while Tak and Met represent comparatively lower binding affinity. Cellular assessment A combination of tak and met reduces TNBC cell viability in vitro MTT assay performed to investigate the cytotoxic effect of Tak, Met, and their combination on the MCF-7, MDA-MB-231, and the 4T1 TNBC cell line. For this aim, first, different BC cell lines were treated with Tak at 0.9 mM and Met at 181 mM for 24 and 48 h. According to Fig. 3, all treated groups significantly decreased the viability of all BC cell lines in a time-dependent manner, especially after 48 h. As shown in Fig. 3A, while single-treated groups reduced 4T1 cell viability only after 48 h, the combination group (Tak + Met) decreased 4T1 cell viability more significantly in both 24 and 48 h (p ≤ 0.0001). Also, about MCF-7 as a hormone receptor-positive human BC cell line, all treatment groups, including the Tak and Met single-treated groups, represent a significant reduction in viability even after 24 h. This reduction increased significantly after 48 h in all treatment groups (Fig. 3B). Additionally, regarding the MDA-MB-231 cell line, similar to MCF-7, all treatment groups exhibited decreased cell viability at both 24 h and 48 h (Fig. 3C). Additionally, synergism analysis revealed that at 48 h, Tak alone induced 13% cell death and metformin alone induced 16% cell death in 4T1 cells. While Tak and Met exhibited 68% cell death at 48 h. According to the Bliss Independence Model, Tak + Met exhibit strong synergistic interaction in reducing 4T1 cell viability. Cytotoxic effect of Met, Tak, and their combination on the viability of different BC cell lines. The MTT assay was used to investigate cell viability of the treatment groups in different BC cell lines compared to the control group. A) Both single and combined groups decreased the viability of 4T1 mouse TNBC cells over time, especially after 48 h. B, C) The human BC cell line also represented the same as 4T1, indicating that Tak, Met, and Tak + Met significantly decreased cell viability of both MCF-7 (hormone-positive) and MDA-MB-231 (human TNBC), especially after 48 h. All data are expressed as mean ± SEM, and one-way ANOVA analysis was performed to compare treatment groups with the control group and Tukey multiple comparison test was performed to detect any differences between treatment groups, * p < 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns, nonsignificant compared to control group Additionally, synergistic interactions were confirmed between Tak and Met in both human breast cancer cell lines at 48 h. About MCF-7 cells, Tak + Met showed strong synergy, while in MDA-MB-231 cells demonstrated moderate synergy. In vivo assessment. Single and combination treatment with TAK1 inhibitor, metformin, and LEME significantly suppresses tumor progression in a BALB/c mouse model of TNBC Considering the significant cytotoxic potential of Tak, Met, and their combination against 4T1 cells in vitro, their in vivo tumor-suppressing efficacy was further investigated using BALB/c mice bearing 4T1 cells. After inoculating 4T1 cancer cells into the flanks of BALB/c mice, once the tumor size reached approximately 50 mm³, the mice were randomly divided into eight groups (Table 3), and treatment was initiated accordingly. Mice, based on their group, received an intravenous (i.v) dose of Tak (0.9 mM in 10 µL equal to 145 µg/kg) three times a week, an intraperitoneal (i.p) dose of Met (150 mg/kg) every day, and oral gavage of LEME (18 mg/mouse in 100 µL) every day for 4 weeks. As presented in Fig. 4, the tumor volume was measured every 3 days during treatment, and tumor weight was measured after the mice were sacrificed at the end of the study. Furthermore, the mice’s weight was also measured every 3 days after treatment for health monitoring. After four weeks, the mice were sacrificed, the tumors were harvested, and their weights and volumes were measured. Based on Fig. 4 B, all treatment groups showed a decrease in tumor volume compared to the control group. Additionally, all combination groups were more effective in tumor suppression than the single treatment groups. Additionally, the Met group demonstrated greater potency in reducing tumor volume compared to the other single treatment groups. Consistent with this reduction in tumor volume, the tumor weight was also significantly decreased in all treated groups (p ≤ 0.0001). Based on Fig. 4C, the Tak+LEME and Tak + Met and Tak+Met+LEME groups reduced tumor weight more than the Met+LEME group. Furthermore, the mice’s body weight was measured for health monitoring. As shown in Fig. 4D, neither group experienced a decrease in body weight; however, the control group exhibited a slight weight loss at the end of the study. It is worth mentioning that, fortunately, none of the groups experienced any mortality during the treatment process, which, along with the stability of body weight, indicates the acceptable safety of the combination of Tak, Met, and LEME, both in single and in combination therapy groups. Table 3In vivo treatment groups and drug administration details in the BALB/c breast cancer modelGroup NumberAdministration and Dose amount1Control (Normal saline, every day i.p)2Met (150 mg/kg, every day, i.p)3Tak (0.9mM/mouse or 145 µg/kg, 3 days per week, i.v)4LEME (18 mg/mouse, every day, gavage)5Tak (0.9mM/mouse or 145 µg/kg, 3 days per week, i.v) + Met (150 mg/kg, every day, i.p)6Tak (0.9mM/mouse or 145 µg/kg, 3 days per week, i.v) + LEME (18 mg/mouse, every day, gavage)7Met (150 mg/kg, every day, i.p) + LEME (18 mg/mouse, every day, gavage)8Tak (0.9mM/mouse or 145 µg/kg, 3 days per week, i.v) + Met (150 mg/kg, every day, i.p) + LEME (18 mg/mouse, every day, gavage) In vivo treatment groups and drug administration details in the BALB/c breast cancer model In Vivo assessment of tumor growth inhibition by treatment groups in BALB/c mice bearing 4T1 TNBC tumors. Mice were treated with intravenous injections of Tak (0.9 mM in 10 µL equal to 145 µg/kg) three times a week, intraperitoneal injections of Met (150 mg/kg) daily, and oral gavage of LEME (18 mg/mouse) every day for 4 weeks. (A) Graphical structure of the in vivo study and treatment processes. (B) Tumors were harvested on the last day of treatment (28th day). C) Tumor volumes are calculated using the calliper and calculated using the specific formula (V = ½ (Length × Width²)), every 3 days during treatment. (D) Tumor weight was measured at the end of the treatment period compared to the control group. (E) No significant changes were observed in the mice’s body weight during the study period. Data are expressed as mean ± SEM (n = 5), and statistical significance analysis was performed using one-way ANOVA for tumor weight and for tumor growth. Also, Tukey multiple comparison test was performed to detect any differences between treatment groups, *:p < 0.05; **:p ≤ 0.01; ***:p ≤ 0.001; ****:p ≤ 0.0001: ns, nonsignificant Combination therapy downregulates exhaustion-associated gene expression in TNBC tumor tissues Real-time PCR was performed to evaluate the effects of treatment on the expression of genes, including NR4A1, TOX, and TIM-3, in tumor tissues. As shown in Fig. 5A, all treatment groups significantly decreased TOX mRNA expression levels compare to control group (p < 0.0001), Fold changes (FCs) were calculated compared to the control group: Met: 0.4, Tak: 0.19, LEME: 0.47, Tak + Met: 0.11, Tak+LEME: 0.08, Met+LEME: 0.29, Tak + Met+LEME: 0.14. Effect of Tak, Met, LEME, and their combination on TOX and NR4A1, important exhaustion-associated transcription factors, and TIM-3, an important inhibitory receptor. (A, B) Real-time PCR was performed on the TNBC tumor tissue of mice to evaluate the gene expression of TOX and NR4A1 as important exhaustion-associated factors. (C) Additionally, the gene expression of TIM-3 was evaluated. Data are expressed as fold change relative to the untreated mice (control group). All data are expressed as mean ± SEM (n = 5), and statistical significance was determined using one-way ANOVA analysis to compare the treated groups with the control group. Tukey’s multiple comparison test determined differences between groups, * p < 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns, nonsignificant On the other hand, according to Fig. 5B, among single treated groups only Met and Tak significantly (p = 0.0290 and p = 0.0057 respectively) decreased NR4A1 expression levels whereas all combined treated groups decreased NR4A1 expression levels more efficient compare to control group (p-values and FCs compared to the control group were: Tak + Met: p = 0.0004, FC: 0.71/ Tak+LEME: p = 0.0002, FC: 0.7/ Met+LEME: p = 0.0054, FC: 0.78/ Tak + Met+LEME: p = < 0.0001, FC: 0.67). Additionally, no significant difference was observed between the treated groups (p > 0.05). Furthermore, based on Fig. 5C, similar to NR4A1 only Met and Tak in single treated groups were able to decrease TIM-3 expression significantly (p = 0.0306 and p = 0.005, FCs: 0.62 and 0.48 respectively), also all combination treated groups except of Met+LEME, decreased TIM-3 expression levels (p-values and FCs respectively: Tak + Met: p = 0.0011, FC: 0.48/ Tak+LEME: p = 0.004, FC: 0.54/ Tak + Met+LEME: p = 0.0004, FC: 0.38). Combination of Met+LEME did not exhibit any synergistic effect. Intrestingly, the combination of Tak with Met and LEME showed a significant synergistic effect in decreasing TIM-3 expression. Notably, the Tak+LEME and Tak + Met+LEME groups had the most significant impact on decreasing both NR4A1 and TOX, as well as TIM-3 expression levels. TAK1 inhibitor–based combination treatment reduces MUC-1 protein expression in TNBC tumor tissues MUC-1 is a neoantigen expressed in many solid cancers, including BC, and contributes to various mechanisms such as metastasis and tumor invasion. Additionally, MUC-1 plays a crucial role in inhibiting the antitumor activity of immune cells. As presented in Fig. 6, Tak significantly reduced MUC-1 expression among single-treated groups. Met also showed a significant effect on decreasing MUC-1 expression, while LEME alone showed no significant impact on MUC-1 expression. In combination groups, all groups showed a significant reduction in MUC-1 expression. It is worth mentioning that the combination of Tak with both Met and LEME showed a significant potency in decreasing MUC-1 expression. Furthermore, when LEME was combined with Tak, it significantly enhanced the potency of Tak in reducing MUC-1, indicating a notable synergistic effect between Tak and LEME. Effect of Tak, Met, LEME, and their combination on MUC-1 expression. Western blot analysis investigated the MUC-1 expression as an essential factor in tumor metastasis and invasion. (A) The picture of blots containing protein bands has been represented. Also, bands were normalized with β-actin protein for quantification. (B) One-way ANOVA analysis was used to compare the treated groups with the control group (mean ± SEM, n = 5), and statistical significance between groups was shown by Tukey’s multiple comparison test, * p < 0.05; ** p ≤ 0.01; *** p ≤ 0.001; ns, nonsignificant Additionally, the Tak + Met+LEME group demonstrated the most significant potency among all treatment groups in reducing MUC-1 expression, indicating a notable synergistic effect between these agents. Combination treatment of Tak, Met and LEME increases the intratumoral population of CD8+CD28+ T cells in a BALB/c mouse model of TNBC An immunofluorescent assay was performed to measure the population of CD8+ T cells that express CD28 in the mouse TNBC tumor tissues. As shown in Fig. 7A, all treatment groups exhibited increased infiltration of CD8 + T cells and CD28 + cells into the tumor tissue. Effect of Tak, Met, LEME, and their combination therapy on the CD8+ CD28+ T cell population. An immunofluorescent assay was used to determine the number of CD8+ CD28+ T cells in the control and treatment groups. (A) Pictures obtained from a fluorescent microscope of study groups, respectively (A: Control, B: Met, C: Tak, D: LEME, E: Tak + Met, F: Tak+LEME, G: Met+LEME, H: Tak + Met+LEME). Blue fluorescence represents DAPI staining, which detects the cells’ nuclei. Green fluorescent staining represents CD8, and red fluorescent staining represents CD28. The merged part represents CD8+CD28+ T cells. (B, C, D) Statistical analysis using one-way ANOVA to determine the significance of differences between treatment groups and the control group. TUKEY test used to investigate differences between groups (mean ± SEM, n = 5), *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; **** p ≤ 0.0001; ns, nonsignificant As presented in Fig. 7B, although all treatment groups led to a significant enhancement in CD8+ T infiltration into the TME (p ≤ 0.0001), among the single treatment groups, the Tak group was more effective than the Met and LEME groups. Additionally, the Met group demonstrated a greater impact than the LEME group in increasing the CD8+ T-cell population. (p ≤ 0.001). In combination treatment groups, Tak + Met+LEME showed the greatest potency in increasing the CD8+ T population; next, the Tak+LEME group ranked second, with a significant difference compared to Tak + Met+LEME (p ≤ 0.01). It is worth mentioning that Tak, combined with LEME (Tak+LEME), exhibited a higher synergistic effect compared to Tak, combined with Met (Tak + Met), and a significant difference was observed between their results (p ≤ 0.0001). Met+LEME had significantly less impact than all other combination-treated groups, but still showed greater impact in CD8 + T cell infiltration than the single-treated groups. In addition, we evaluated CD28 expression as an essential co-stimulatory receptor in T lymphocytes, especially in CD8+ T cells, which regulates their activation and anti-tumor function (Fig. 7C). Similar to CD8 expression, all treated groups showed a significant increase in CD28 expression in the TME (p ≤ 0.0001). However, in this case, there was no significant difference between the Met and LEME groups (ns: nonsignificant). In combination treatment groups, the Tak + Met+LEME-treated group had the most potent effect compared to the other treated groups. After that, Tak+LEME showed a remarkable result. The difference between Tak+LEME and Tak + Met remained significant. Considering both markers together, we measured the population of T lymphocytes expressing both CD8 and CD28 as a sign of functional CD8+ T cells with high anti-tumor function, distinct from exhausted CD8+ T cells. All treatment groups enhanced the CD8+ CD28+ T Cells population in tumor tissue (p < 0.0001). Tak+LEME and Tak + Met+LEME were more efficient in improving CD8+ CD28+ T cells among treatment groups (Fig. 7D). It is important to note that combining all agents (Tak + Met+LEME) or TAK+LEME resulted in the highest potency in expanding the population of CD8+ CD28+ T cells, and there was no significant difference observed between these two groups. Discussion In this study, we evaluated the effect of single and combinatorial treatments of Met and Tak, along with LEME, in a mouse model of TNBC, focusing on tumor growth inhibition effect, exhaustion gene expression, and CD8+CD28+ T cell infiltration as a crucial specific immune response against cancer cells in tumor tissues. The molecular docking results revealed that Tak may have had the strongest binding affinity with both NR4A1 and TOX compared to Met, which was predicted to have a moderate binding affinity. For TIM-3, the standard ligand exhibited the highest affinity, while Tak and Met showed weaker interactions. Taken together, Tak predicted to have a higher binding affinity with NR4A1 and TOX, suggesting its potential role in targeting T cell exhaustion by interacting with transcription factors involved in this process. According to our study, all treatment groups were effective in preventing tumor growth, as indicated by both tumor volume and tumor weight, compared to the control group. In addition, all treatment groups were effective in reducing TOX expression, a crucial factor in the induction of the dysfunctional T cells in chronic immune responses. Interestingly, the combination of Tak with metformin or LEME resulted in a synergistic reduction of TOX expression. It is worth mentioning that the current study employed fixed doses based on previous studies; future investigations should include systematic dose-response evaluations to determine the optimal dose for this combination therapy, thereby enhancing therapeutic efficacy while minimizing potential adverse effects. Immune system cells, particularly CD8 + T cells, play a crucial role in controlling tumor invasion [50], and their functional state correlates with their anti-cancer activity [51]. A previous study found that Lentinula edodes contains special polysaccharides that stimulate the expansion of CD8+ T lymphocytes [52]. In a mouse tumor model, treatment with small molecules blocking TAK1 activity significantly increased the frequency of CD8+ T cells in tumors and enhanced their activation [53]. Additionally, a recent in vivo study on pancreatic ductal adenocarcinoma showed that TAK1 inhibition was associated with increased intratumoral abundance of CD8+ and CD4+ T cells, as well as an increase in CD8+Granzyme B+ cytotoxic T cells [54]. In line with previous studies, the combination of TAK1 inhibitor (Tak) with LEME can significantly increase the infiltration of CD8+CD28+ T cells into tumor tissue. Although the combination of all three drugs has shown similar results, there was no significant difference between this Tak + Met+LEME group and the Tak+LEME group, suggesting that the addition of Met did not enhance the potency of Tak+LEME in promoting cytotoxic T cell infiltration. Although the difference in results between the CD28-expressing cell population and the CD8+CD28+ T cell population suggests that the combination of Tak+LEME with Met plays a major role in recruiting other cells that express CD28 on their surface, such as helper T cells, which are crucial for the activation of CD8 + T cells. This enhancement in the population of TME-infiltrated CD8+ T cells could result from an increase in CD8+ T cell homing to tumor tissue or a reversal of the decreased CD28 expression on CD8+ T cells that occurs in chronic inflammatory environments, such as TME in solid cancers [55]. Many studies have indicated that inflammatory cytokines are one of the most critical factors in TME, playing a crucial role in tumor cell invasion and suppressing the immune system’s anti-tumor function by inducing non-functional phenotypes in immune cells [56]. As we previously investigated, combination therapy containing various anticancer compounds represents a promising approach for cancer treatment [57]. TNF-α is as an essential cytokine among various inflammatory cytokines in the TME, which functions as a double-edged sword by playing a notable role in tumor cell survival by increasing anti-apoptotic factors, such as Bcl-2, through NF-κB, MAPKs, and Akt signaling pathways [58]. On the other hand, TNF-α can induce extracellular apoptosis in cancer cells by activating Caspase-8 and FADD complex, and also activate immune cells by increasing cytokine secretion [59]. Recent studies have revealed that Tak has a major role in shifting the inflammatory pathway of TNF-α to pro-apoptotic effects [60]. Recent studies have demonstrated that TAK1 is highly expressed in human TNBC cells and plays a crucial role in cancer growth and metastasis following stimulation with TNF-α, by increasing matrix metalloprotease (MMPs) and activating NF-κB signaling. Also, inhibition of the TNF-α–TAK1–MMP9 axis decreases the viability of human TNBC cells [61]. Many studies have reported that Met reduces cancer cell viability and sensitizes them to other chemotherapy agents by activating AMPK and subsequently inhibiting the mTOR, PI3K/AKT pathway, and increasing autophagy in cancer cells [62–64]. Abdolvand et al. demonstrated that Met has a significant synergistic effect when combined with Tak in reducing the viability of different human cancer cells, including metastatic TNBC cells [65]. Our study on 4T1 mouse TNBC cells and human luminal breast cancer cell line (MCF-7) and human metastatic TNBC cell line (MDA-MB231) revealed that both Tak and Met decreased the viability of cancer cells in a synergistic manner. Additionally, synergy analysis of Tak and Met utilizing the Bliss Independence Model revealed consistent synergistic anti-proliferative effects across both mouse (4T1) and human (MCF-7, MDA-MB-231) breast cancer cell lines. Some studies have reported significant anti-cancer effects and potent immunostimulatory properties of various Lentinula edodes compounds, alone and in combination with other anti-cancer agents. A study on lung adenocarcinoma demonstrated that LEME compounds significantly modulated the TME by enhancing the NK cell population and activation markers, such as NKG2D and NKp30, on their surface [66]. A study on breast cancer revealed that LEME compounds inhibits the proliferation of human MCF-7 cells and induces apoptosis by increasing autophagy, activating caspase-7, and increasing the Bax/Bcl-2 ratio [67]. MUC-1 is a neoantigen expressed in different solid cancers, including BC, playing a notable role in cancer metastasis [68]. MUC-1 activates TAK-1 directly, leading to activation of the NFκB pathway, which results in survival and metastasis in BC cells [69]. Some studies indicate that Met reduces MUC1 protein expression in women with BC [70]. A study has also revealed that MUC-1 and PD-L1 are upregulated in TNBC, which is essential in promoting its invasive phenotype and reducing the function of immune cells. Thus, targeting MUC-1 has been associated with a reduction in PD-L1, enhanced infiltration of CD8+ T cells, and increased tumor cell elimination [71]. In our study, Western blot analysis on MUC1 expression revealed differential effects of Tak, Met, and LEME. Among the single-treatment groups, TAK had the most significant suppressive effect on MUC-1. Metformin also reduced MUC-1 expression, suggesting a relationship between AMPK activation and the inhibition of MUC–1 protein expression. On the other hand, LEME showed no significant impact on MUC-1 expression. Surprisingly, among the combination treatment groups, the Tak+LEME and Tak + Met+LEME groups exhibited a notable reduction in MUC-1 protein expression, suggesting a synergistic mechanism between Tak and LEME. Although the combination of Tak and Met in the inhibition of MUC1 expression was more efficient compared to their single treatment groups, this effect was less potent than the combination of Tak and LEME. This significant synergistic effect may refer to the simultaneous inhibition of TAK-1 signaling by Tak and activation of AMPK by Met, along with the LEME effect on cancer cells. We evaluated the expression of senescence/exhaustion-associated transcription factors NR4A and TOX. While all treated groups significantly decreased TOX expression, combined treated groups, especially those involving Tak, such as Tak + Met and Tak+LEME, showed greater efficiency in reducing TOX gene expression. There was no significant difference between single-treated groups and combined groups. On the other hand, NR4A1 gene expression analysis in the treated groups demonstrated that only Tak or Met, among the single-treated groups, were able to decrease NR4A1 gene expression. In contrast, among combination-treated groups, all combination groups significantly reduced NR4A1 gene expression levels. It is worth mentioning that the power of the related drug was more efficient in the reduction of TOX expression rather than NR4A expression. Furthermore, we examined TIM-3 expression, a crucial inhibitory receptor that is increased in exhausted CD8+ T cells and plays a key role in suppressing the anti-tumor function of T cells in the TME. Tak effectively decreased TIM-3 gene expression among single-treated groups. While combining Tak with other agents did not enhance its potency on TIM-3, in contrast to its effects on TOX and NR4A1, the combination of Tak + Met+LEME resulted in greater potency in inhibiting TIM-3 expression. Recently, a study reported that Lentinula edodes decreases TIM-3 expression and a novel exhaustion-related marker CD317, suggesting that it may interfere with a distinct exhaustion pathway [72]. In line with these studies, all treatment groups significantly decreased TIM-3 expression in our study. Considering the promising role of Lentinula edodes compounds combined with other anti-cancer agents, such as Met, along with the advantages of TAK1 inhibition on tumor cells and immune cells, our study found that LEME, in combination with Met and, more specifically, with TAK, significantly suppressed tumor growth and progression. Nevertheless, this study contains several limitations, and further investigation is required. Future research should focus on further analysis to investigate the Met and Tak1 mechanisms and detect the active components of LEME, in order to reveal the exact signaling pathways responsible for this considerable synergism and refine the potency of this combination therapy. Additionally, future studies should investigate the safety and efficacy of this combination therapy, as well as its potential benefits when combined with different immunotherapy approaches, such as checkpoint blockade. Additionally, gene expression analysis was performed on bulk tumor tissue, evaluating overall treatment effects but not distinguishing changes in cancer cells compare to immune cells. Future studies should focus on immune cell-specific analyses, including characterization of signaling pathways along with protein expression, and assessing the functional situation (e.g., granzyme B and IFN-γ production) to fully determine any alteration in immune cells function, specially CD8+ T cell after treatment. Additionally, the mechanisms underlying MUC-1 suppression by Tak and its impact on metastatic potential require further investigation. Conclusion Generally, the combination of Tak, Met, and LEME has revealed a promising outcome in tumor growth inhibition through alleviating T cell exhaustion by reducing gene expression of exhaustion-related transcription factors such as NR4A1 and TOX, and also decreasing expression of TIM-3, an important inhibitory receptor in CD8+ T cells, and increasing the population of CD8+ CD28+ cytotoxic T cells in TME. Additionally, this combination therapy reduced MUC-1 protein expression, a factor that plays a crucial role in tumor metastasis and cancer invasion. Altogether, the dual role of Tak, Met, and LEME combination on tumor progression inhibition and immune system activation could be an effective way for the treatment of solid tumors such as breast cancer. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Supplementary Material 8 Supplementary Material 9 Acknowledgements The authors gratefully acknowledge the Basic Health Research Center for providing the facilities and resources that enabled the conduct of this research. Abbreviations Breast Cancer Triple-Negative Breast Cancer Tumor Microenvironment Programmed Cell Death Protein 1 T-cell Immunoglobulin and Mucin-Domain Containing-3 Nuclear Receptor Group 4 Family A1 Thymocyte Selection-Associated HMG-Box Protein Transforming growth factor-β-activated kinase 1 Takinib Metformin Lentinula edodes mycelia extract Natural Killer Group 2 Member D Natural Cytotoxicity Receptor Transmembrane Glycoprotein Mucin 1 3-(4, 5-dimethylthiazolyl-2)-2, 5-Diphenyltetrazolium Bromide Dimethyl Sulfoxide Horseradish Peroxidase 4’,6-Diamidino-2-Phenylindole Protein Data Bank AutoDock Tools 1640–Roswell Park Memorial Institute Fetal Bovine Serum Complementary DNA Quantitative PCR Radioimmunoprecipitation Assay Buffer Poly Vinylidene Fluoride Sodium Dodecyl-Sulfate Bovine Serum Albumin Enhanced Chemiluminescence Heat-Induced Epitope Retrieval Matrix Metalloprotease Programmed Death-Ligand 1 Phosphate Buffered Saline Author contribution Amirsaeid Mahdavi: Conceptualization, Data curation, Methodology, Investigation, Resources, Writing – original draft. Nader Bagheri: Methodology, Investigation, Resources, Writing – original draft. Francesco M. Marincola: Reviewed and edited the manuscript, rechecked the results and data analysis, and contributed to the final manuscript revision. Pegah Khosravian-Dehkordi: Methodology, Data curation, Investigation, Resources. Mahdi Ghatrehsamani: Corresponding author, Validation, Investigation, Project administration, Supervision, Resources, Funding acquisition, Review & Editing. Funding This work was supported by master’s thesis grants from Shahrekord University of Medical Sciences, Shahrekord, Iran, awarded to Amir Saeid Mahdavi with grant numbers 4719 and 4747. Data availability The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate All animal experiments in this study were conducted in strict accordance with the ethical guidelines and standards set by the Laboratory Animal Center of Shahrekord University of Medical Sciences, Shahrekord, Iran (IR.SKUMS.AEC.1403.061 and IR.SKUMS.AEC.1403.062). A total of 40 mice were used in this research, housed under controlled environmental conditions with a 12-hour light/dark cycle and fed according to institutional guidelines. At the end of the study, all mice were sacrificed in accordance with approved ethical protocols to minimize suffering. All procedures fully complied with the ethical standards for the care and use of laboratory animals, including the ARRIVE guidelines and the NIH Guide for the Care and Use of Laboratory Animals. The procedures also followed the guidelines provided by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Consent for publication Not applicable. Competing interests The authors have no conflict of interest to declare in this manuscript, and Francesco M. Marincola serves as the Editor in Chief of the Journal of Translational Medicine. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Supplementary Material 8 Supplementary Material 9 Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.